Inventor · disambiguated record
Douglas L. Sheridan
Also filed as: SHERIDAN DOUGLAS L
25 granted patents·10 pending applications·437 citations·filing 2011–2025
97Inventor score
Top patents by PatentIndex Score
35 records- 0199US9206251B2Nucleic acids encoding anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Dec 8, 2015·36 cites·36 claims
- 0299US9107861B1Methods of treating C5 mediated complement-associated conditions with anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Aug 18, 2015·58 cites·18 claims
- 0399US9079949B1Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Jul 14, 2015·182 cites·20 claims
- 0498US11434280B2Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2020·Granted Sep 6, 2022·10 cites·18 claims
- 0598US9663574B2Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2016·Granted May 30, 2017·24 cites·10 claims
- 0697US10584164B2Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodiesALEXION PHARMA INC·Filed 2019·Granted Mar 10, 2020·11 cites·10 claims
- 0797US10227400B2Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodiesALEXION PHARMA INC·Filed 2017·Granted Mar 12, 2019·14 cites·7 claims
- 0897US9803007B1Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2017·Granted Oct 31, 2017·14 cites·7 claims
- 0997US9371377B2Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Jun 21, 2016·22 cites·17 claims
- 1095US9011852B2Anti-C5a antibodiesROTHER RUSSELL P·Filed 2011·Granted Apr 21, 2015·25 cites·18 claims
- 1194US9221901B2Methods of treating complement-associated disorders with anti-C5a antibodiesALEXION PHARMA INC·Filed 2015·Granted Dec 29, 2015·11 cites·16 claims
- 1293US9371378B1Anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted Jun 21, 2016·7 cites·10 claims
- 1391US9309310B2Nucleic acids encoding anti-C5a antibodiesALEXION PHARMA INC·Filed 2015·Granted Apr 12, 2016·7 cites·20 claims
- 1490US12221473B2Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereofALEXION PHARMA INC·Filed 2022·Granted Feb 11, 2025·1 cites·13 claims
- 1589US9469690B2Methods of treating complement-associated disorders with anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted Oct 18, 2016·4 cites·14 claims
- 1689US9434784B1Nucleic acids encodng anti-C5A antibodiesALEXION PHARMA INC·Filed 2016·Granted Sep 6, 2016·4 cites·27 claims
- 1789US2024141024A1Anti-c5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2023·Application pending·0 cites
- 1885US10450370B2Anti-C5a antibodiesALEXION PHARMA INC·Filed 2018·Granted Oct 22, 2019·2 cites·20 claims
- 1984US11498960B2Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereofALEXION PHARMA INC·Filed 2018·Granted Nov 15, 2022·2 cites·14 claims
- 2084US9963503B2Methods of producing anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted May 8, 2018·2 cites·2 claims
- 2184US2023159627A1Anti-c5a antibodiesALEXION PHARMA INC·Filed 2022·Application pending·0 cites
- 2281US11407821B2Anti-C5A antibodiesALEXION PHARMA INC·Filed 2019·Granted Aug 9, 2022·0 cites·24 claims
- 2378US2025145698A1Anti-c5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2025·Application pending·0 cites
- 2473US12497445B2Monovalent anti-properdin antibodies and antibody fragmentsALEXION PHARMA INC·Filed 2021·Granted Dec 16, 2025·0 cites·8 claims
- 2571US11802154B2Humanized anti-CD200 antibodies and uses thereofALEXION PHARMA INC·Filed 2018·Granted Oct 31, 2023·1 cites·19 claims
- 2664US2025163138A1Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereofALEXION PHARMA INC·Filed 2025·Application pending·0 cites
- 2763US12240893B2Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)ALEXION PHARMA INC·Filed 2019·Granted Mar 4, 2025·0 cites·19 claims
- 2861US11198725B2Monovalent anti-properdin antibodies and antibody fragmentsALEXION PHARMA INC·Filed 2018·Granted Dec 14, 2021·0 cites·7 claims
- 2959US2024018220A1Methods of treating patients having complement disorders using anti-c5 antibodiesALEXION PHARMA INC·Filed 2021·Application pending·0 cites
- 3058US2024141066A1Method of Administering Anti-HPA-1a Monoclonal AntibodyRALLYBIO IPA LLC·Filed 2022·Application pending·0 cites
- 3158US2025003985A1Assays for Quantification of Anti-HPA-1a AntibodiesRALLYBIO IPA LLC·Filed 2022·Application pending·0 cites
- 3257US2024141067A1Administration of Anti-HPA-1a AntibodiesRALLYBIO IPA LLC·Filed 2022·Application pending·0 cites
- 3352US2025145700A1Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)ALEXION PHARMA INC·Filed 2025·Application pending·0 cites
- 3445US2021388070A1Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditionsALEXION PHARMA INC·Filed 2019·Application pending·0 cites
- 3541US9803005B2Humaneered anti-factor B antibodyALEXION PHARMA INC·Filed 2013·Granted Oct 31, 2017·0 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when Douglas L. Sheridan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →